Earnings History Data for Avalo Therapeutics, Inc. (AVTX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Avalo Therapeutics, Inc.

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.

Release Date	Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
09-11-2023	PM	AVTX	Avalo Therapeutics	2.00	-0.11	-1.10	0.00	Avalo Therapeutics GAAP EPS of -$0.11 beats by $0.99, revenue of $0.24M misses by $0.76M [11/9/2023 7:46 AM]	0.0954	-0.01 (-12.48%)	0.11	0.0 (1.28%)	0.08 - 6.60	31,475,864	34,220,000	6,230,328
Avalo Therapeutics GAAP EPS of -$0.11 beats by $0.99, revenue of $0.24M misses by $0.76M [11/9/2023 7:46 AM]
07-11-2022	PM	AVTX	Avalo Therapeutics	65.00	0.34	-1.03	0.00	Avalo Therapeutics GAAP EPS of $0.34 beats by $1.04, revenue of $14.95M [11/7/2022 8:22 AM]	6.70	-0.08 (-1.18%)	6.78	0.0 (0.00%)	2.42 - 28.68	34,838	20,000	107
Avalo Therapeutics GAAP EPS of $0.34 beats by $1.04, revenue of $14.95M [11/7/2022 8:22 AM] Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates [Nov-07-22 07:30AM] Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million [Nov-07-22 07:00AM]
04-08-2022	PM	AVTX	Avalo Therapeutics	33.00	-1.38	-1.80	0.00	Avalo Therapeutics GAAP EPS of -$1.38 beats by $0.37, revenue of $1.03M beats by $0.29M [8/4/2022 9:01 AM]	4.01	0.36 (9.86%)	3.92	-0.40 (-9.26%)	2.42 - 38.88	141,876	40,000	51,552
Avalo Therapeutics GAAP EPS of -$1.38 beats by $0.37, revenue of $1.03M beats by $0.29M [8/4/2022 9:01 AM] Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates [Aug-04-22 07:30AM]
05-05-2022	PM	AVTX	Avalo Therapeutics	48.00	-0.20	-0.14	0.00	Avalo Therapeutics GAAP EPS of -$0.20 misses by $0.08, revenue of $1.17M beats by $0.65M [5/5/2022 8:55 AM]	0.3277	-0.07 (-16.81%)	0.40	0.01 (1.55%)	0.31 - 3.70	1,091,035	470,000	905
Avalo Therapeutics GAAP EPS of -$0.20 misses by $0.08, revenue of $1.17M beats by $0.65M [5/5/2022 8:55 AM] Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates [May-05-22 07:30AM]
09-11-2021	AH	AVTX	Avalo Therapeutics, Inc.	266.19	-0.17	-0.19	-0.16	Avalo Therapeutics EPS beats by $0.01, beats on revenue [11/9/2021 4:54 PM]	2.28	-0.04 (-1.72%)	2.21	-0.11 (-4.74%)	1.99 - 4.50	243,289	330,000	507
Avalo Therapeutics EPS beats by $0.01, beats on revenue [11/9/2021 4:54 PM] Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates [Nov-09-21 04:01PM]